NZ553653A - Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid - Google Patents

Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid

Info

Publication number
NZ553653A
NZ553653A NZ553653A NZ55365305A NZ553653A NZ 553653 A NZ553653 A NZ 553653A NZ 553653 A NZ553653 A NZ 553653A NZ 55365305 A NZ55365305 A NZ 55365305A NZ 553653 A NZ553653 A NZ 553653A
Authority
NZ
New Zealand
Prior art keywords
barbituric acid
dosage form
oral dosage
diphenyl
administration
Prior art date
Application number
NZ553653A
Other languages
English (en)
Inventor
Daniella Gutman
Avraham Yacobi
Daniel Moros
Barrie Levitt
Howard Rutman
Original Assignee
Taro Pharma Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharma Ind filed Critical Taro Pharma Ind
Publication of NZ553653A publication Critical patent/NZ553653A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C07D239/64—Salts of organic bases; Organic double compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ553653A 2004-08-10 2005-08-10 Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid NZ553653A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60032704P 2004-08-10 2004-08-10
PCT/US2005/028380 WO2006026095A2 (en) 2004-08-10 2005-08-10 Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid

Publications (1)

Publication Number Publication Date
NZ553653A true NZ553653A (en) 2010-06-25

Family

ID=34942111

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ553653A NZ553653A (en) 2004-08-10 2005-08-10 Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid

Country Status (14)

Country Link
EP (2) EP1625848A1 (enExample)
JP (2) JP2008509914A (enExample)
KR (2) KR20070074549A (enExample)
CN (2) CN102512422A (enExample)
AT (1) ATE510541T1 (enExample)
AU (1) AU2005280419B2 (enExample)
BR (1) BRPI0513337A (enExample)
CA (1) CA2576832C (enExample)
IL (1) IL181247A (enExample)
MX (1) MX2007001655A (enExample)
NZ (1) NZ553653A (enExample)
SG (1) SG163500A1 (enExample)
WO (1) WO2006026095A2 (enExample)
ZA (1) ZA201106419B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US7683071B2 (en) 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
CN100502871C (zh) 2002-12-11 2009-06-24 塔罗制药工业有限公司 巴比土酸衍生物在制备用于治疗运动障碍的药物中的应用
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
CN102863579B (zh) * 2012-09-14 2014-02-05 东南大学 一种巴比妥酸螯合树脂及其制备方法和应用
KR102162003B1 (ko) 2014-04-14 2020-10-06 삼성전자주식회사 무선 네트워크 연결 제어 방법 및 장치
KR101822417B1 (ko) * 2017-06-14 2018-01-29 주식회사 청도제약 인간의 체액에서 산화 스트레스를 측정하기 위한 방법
GB202100352D0 (en) * 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2119701A (en) * 1934-06-29 1938-06-07 Winthrop Chem Co Inc Alkoxyalkyl mercury nitrogen compounds
IL69722A (en) * 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
DE4433764A1 (de) * 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
US6093820A (en) * 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
EP1311270B1 (en) * 2000-07-26 2008-01-09 Taro Pharmaceutical Industries Limited Non-sedating barbiturate compounds as neuroprotective agents
CN1896084A (zh) * 2002-01-30 2007-01-17 塔罗制药工业有限公司 非镇静性巴比土酸衍生物
CN100502871C (zh) * 2002-12-11 2009-06-24 塔罗制药工业有限公司 巴比土酸衍生物在制备用于治疗运动障碍的药物中的应用
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid

Also Published As

Publication number Publication date
CA2576832A1 (en) 2006-03-09
WO2006026095A2 (en) 2006-03-09
EP1781294A4 (en) 2007-12-26
SG163500A1 (en) 2010-08-30
ATE510541T1 (de) 2011-06-15
HK1108313A1 (en) 2008-05-02
CN102512422A (zh) 2012-06-27
BRPI0513337A (pt) 2008-05-06
AU2005280419B2 (en) 2010-09-23
EP1781294B1 (en) 2011-05-25
EP1625848A1 (en) 2006-02-15
JP2013177442A (ja) 2013-09-09
MX2007001655A (es) 2007-04-23
ZA201106419B (en) 2012-05-30
IL181247A0 (en) 2007-07-04
JP2008509914A (ja) 2008-04-03
CA2576832C (en) 2013-06-11
KR20120130256A (ko) 2012-11-29
IL181247A (en) 2012-05-31
AU2005280419A1 (en) 2006-03-09
WO2006026095A3 (en) 2007-02-01
EP1781294A2 (en) 2007-05-09
KR20070074549A (ko) 2007-07-12
CN101052403A (zh) 2007-10-10

Similar Documents

Publication Publication Date Title
US8076346B2 (en) Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
JP2013177442A (ja) ５，５−ジフェニルバルビツル酸の改良されたバイオアベイラビリティ及び高められた脳送達のための組成物及び方法
US20240100054A1 (en) Pharmaceutical compositions comprising sepiapterin and uses thereof
US11229652B2 (en) Treatments for autoimmune disease
US20090124639A1 (en) valacyclovir formulations
CZ20033456A3 (en) Pharmaceutical compositions comprising adsorbates of amorphous drug
KR20210038848A (ko) 세피아프테린의 제약상 허용되는 염
JP2008543976A (ja) ペメトレキセド二酸の医薬上許容される凍結乾燥塩の調製方法
TW202214555A (zh) 茚化合物、其醫藥組合物及其治療應用
KR102276281B1 (ko) 의약으로 사용하기 위한 펄린돌 광학이성질체의 약학적으로 허용가능한 염
US9095585B2 (en) Bioavailable compositions of amorphous piperidinyl compounds
US20200392084A1 (en) Sulfasalazine salt compositions and methods of using the same
WO2007074477A2 (en) Metaxalone polymorphs
HK1108313B (en) Composition for improved bioavailability and enhanced brain delivery of 5, 5-diphenyl barbituric acid
CN113582927A (zh) 塞来昔布与普瑞巴林共无定型物及其制备方法
CN112457291B (zh) 苯并硫代吡喃酮类化合物的盐及其制备方法和用途
CA2469656A1 (en) Amorphous form of 2-n-butyl-3-( (2-(1h-tetrazol-5-yl) (1,1'-biphenyl)-4-yl) methyl) -1,3-diazaspiro (4,4') non-1-en-4-one
HK1171958A (en) Composition and method for improved bioavailability and enhanced brain delivery of 5, 5-diphenyl barbituric acid
US20120165315A1 (en) Meptazinol carbamate prodrug salts
CN114533712A (zh) 减轻胃肠道副作用的药学组合物
CN120865120A (zh) 一种利鲁唑对甲苯磺酸盐及其制备方法
HK1110515A (en) Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed